ABSTRACT Methamphetamine (METH) is a major addictive drug of abuse in the United States and worldwide, and its use is linked to HIV acquisition. The encapsulated fungus Cryptococcus neoformans is the most common cause of fungal meningitis in patients with AIDS. In addition to functioning as a central nervous system stimulant, METH has diverse effects on host immunity. Using a systemic mouse model of infection and in vitro assays in order to critically assess the impact of METH on C. neoformans pathogenesis, we demonstrate that METH stimulates fungal adhesion, glucuronoxylomannan (GXM) release, and biofilm formation in the lungs. Interestingly, structural analysis of the capsular polysaccharide of METH-exposed cryptococci revealed that METH alters the carbohydrate composition of this virulence factor, an event of adaptation to external stimuli that can be advantageous to the fungus during pathogenesis. Additionally, we show that METH promotes C. neoformans dissemination from the respiratory tract into the brain parenchyma. Our findings provide novel evidence of the impact of METH abuse on host homeostasis and increased permissiveness to opportunistic microorganisms. 
ence of glucuronoxylomannan (GXM), the major capsular polysaccharide of C. neoformans, in tissue is believed to be a major contributor to C. neoformans pathogenesis since this compound is copiously released during infection and has been associated with a variety of immunosuppressive effects (12) . Furthermore, GXM release is essential for cryptococcal biofilm formation (13) , a strategy associated with chronic infections as a result of acquired resistance to host immune mechanisms (14) and antimicrobial therapy (15) . Biofilm formation by C. neoformans follows a discrete sequence of events, including fungal surface adhesion, microcolony formation, and matrix production (13) .
During cryptococcosis, fungemia is detected in~50% of HIVinfected patients (16) . The correlation between fungemia and dissemination, including brain invasion, has been made for experimental models of cryptococcosis (17) , and fungemia is identified as an independent parameter of failure of host effector responses (16) . Brain invasion by C. neoformans requires viable yeast cells, and there is evidence of a transcellular passage of the fungus across the blood-brain barrier (BBB) (18, 19) . In fact, we recently showed that BBB disruption accelerates transmigration of C. neoformans into the brain parenchyma after systemic infection (20) . In the present study, we hypothesized that METH in lung tissues exacerbates cryptococcal infection, promoting fungal biofilm formation and dissemination to the CNS. Using a systemic mouse model of infection, we demonstrate that METH stimulates C. neoformans adhesion, GXM release, and biofilm formation in the lungs and accelerates fungal cell migration to the brain.
RESULTS

METH exacerbates pulmonary cryptococcosis.
Administration of METH significantly accelerated the time to death of C. neoformans-infected mice relative to that of control mice (P Ͻ 0.01). On day 9 postinfection, 100% of METH-treated mice were dead, compared to 50% of the control mice. On average, METHtreated mice died 6 days postinfection versus 9 days postinfection for the control mice (Fig. 1A) . In mice infected with 10 6 C. neoformans cells, pulmonary fungal burdens in METH-treated animals were significantly higher than in control mice (P Ͻ 0.05) (Fig. 1B) . In addition, GXM was more extensively released by C. neoformans in the lungs of METH-treated mice than in those of controls (Fig. 1C) .
Histological examination revealed that mice treated with METH prior to infection with 10 6 C. neoformans cells had a baseline abnormal morphology characterized by peribronchial inflammation and inflammatory cells present within alveoli (Fig. 1E ). This finding suggests that METH deregulates host homeostasis. Significantly, infected METH-treated mice had large numbers of fungal cells and reduced inflammation as well as massive accumulations of fungal polysaccharide. In contrast, the lungs of control mice showed localized inflammation and dense cellular infiltration (Fig. 1D) . In summary, our findings demonstrate that METH administration enhances disease progression by increasing pulmonary fungal burden and amassing of polysaccharide, leading to the inhibition of the host cellular infiltrates.
METH enhances fungal adhesion to human epithelial lung cells. We investigated the ability of C. neoformans to adhere to A549 epithelial lung cells after METH treatment (Fig. 2) . METH significantly increased the ability of cryptococcal cells to adhere to A549 epithelial cells relative to that of untreated cells (P Ͻ 0.05 and P Ͻ 0.001 for 25 and 50 M METH, respectively) ( Fig. 2A) .
Fluorescence microscopy confirmed that METH enhances the interaction of C. neoformans (blue) with epithelial cells (red) compared to the interaction of untreated controls (Fig. 2B) , revealing that multiple yeast cells frequently engaged single METH-exposed epithelial cells.
The surface charge of cryptococcal cells was measured (Fig. 2C) . Previous studies have shown that the polysaccharide capsule of C. neoformans is responsible for a high negative charge on the surfaces of the cells (21) . Exposure to increasing concentrations of METH significantly increased the net negative surface charge of the cryptococcal cells (Ϫ44.66 Ϯ 6.42 and Ϫ49.58 Ϯ 5.87 for 25 and 50 M METH, respectively) compared to that of nonexposed cryptococcal cells (Ϫ29.65 Ϯ 5.74) (P Ͻ 0.05 and P Ͻ 0.001 for 25 and 50 M METH, respectively).
METH enhances GXM release in vitro. C. neoformans sheds large amounts of polysaccharide into culture media and infected tissues (22) . The capsule size of C. neoformans H99 cells was measured in cells grown in the presence or absence of METH to determine whether or not this drug altered capsule growth and to assess its effect on the quantity of GXM released in culture. After 24 h, the capsule size of C. neoformans cells grown in the presence of METH (2.57 Ϯ 0.52 m and 2.20 Ϯ 0.66 m with 25 and 50 M METH, respectively) was significantly reduced compared with the capsule size of the untreated controls (2.97 Ϯ 0.70 m) (P Ͻ 0.05) (Fig. 3A) . Conversely, C. neoformans polysaccharide capsule release in the presence of METH was significantly greater than in the absence of the drug (P Ͻ 0.05 and P Ͻ 0.001 for 25 and 50 M, respectively) (Fig. 3B) . Using light microscopy, we demonstrated that METH significantly reduced the quantity of capsular polysaccharide (Fig. 3C) , suggesting that METH stimulates GXM release into the medium.
METH alters C. neoformans capsular polysaccharide size and composition. We analyzed the size distribution of polysaccharide from C. neoformans capsule molecules cultivated with or without METH (Fig. 4) . The capsular polysaccharide molecules of METH-treated yeast cells exhibited, on average, a smaller diameter (941.0 Ϯ 11.9 nm) (Fig. 4B) (Fig. 4B) . Similarly, two different populations with respect to polysaccharide size were present in untreated cells (Fig. 4A) . The size range for each population was 2.03 to 288.1 and 1,405.9 to 3,786.7 nm, with the highest values at 193.8 and 2,089.7 nm, respectively. Using immunofluorescence, we demonstrated a significant reduction in capsule-specific monoclonal antibody (MAb) 18B7 binding to cryptococcal cells treated with METH relative to that of control yeast cells (Fig. 4C) , suggesting that METH might be capable of altering capsular polysaccharide synthesis and/or structure, resulting in a different capsular surface with altered epitope density and/or accessibility. METHinduced alterations of the cryptococcal cell surface might have adverse implications on host-pathogen interactions and enhance pathogenesis.
Preparations of cryptococcal polysaccharide capsule material released in culture medium from strain H99 after incubation in the absence or presence of 25 M METH were analyzed for carbohydrate composition by combined gas chromatography-mass spectrometry (Table 1) . METH-treated cultures (514.5 mg/ 500 ml) displayed higher capsular mass than controls (359.6 mg/ 500 ml). The glycosyl composition of capsular polysaccharide isolated from METH-treated cultures showed higher quantities of xylose (30 versus 28.1%) and glucose (11.4 versus 3.7%) and lower quantities of glucuronic acid (10.9 versus 11.3%) and mannose (45.8 versus 53.4%) than the glycosyl composition of untreated cultures (Table 1) .
METH enhances C. neoformans adhesion, capsular polysaccharide release, and biofilm formation. To determine the mechanism by which METH promotes C. neoformans adhesion and biofilm formation in the lungs, the spot enzyme-linked immunosorbent assay (ELISA) was utilized. This assay was used to examine local release of capsular polysaccharide by attached cryptococcal cells and the role of this polysaccharide in C. neoformans biofilm formation. Light microscopy was used to quantify the number of cells that attached, as measured by spot formation (Fig. 5A ). METH-treated C. neoformans cells produced significantly larger numbers of spots than control cells (P Ͻ 0.05) after a 0.5-h incubation period (Fig. 5B) . However, the number of spots observed for control cryptococcal cells increased significantly relative to time, although the number remained significantly less than that for METH-exposed cells at each time interval examined.
In addition, the surface areas of the spots were measured by tracing the circumference of a whole spot left by the organism at the equatorial plane (area ϭ r 2 ) (Fig. 5C ). This was done to determine the impact of METH on the area involved in the binding of GXM released by attached C. neoformans cells. Spots from METH-treated C. neoformans cells were significantly larger than those from untreated cells with 50 M METH after 0.5 h and with 25 M METH by 1 h of incubation (P Ͻ 0.001).
C. neoformans strain H99 biofilms treated with METH showed a significant dose-dependent increase in metabolic activity when (Fig. 5E) .
METH facilitates C. neoformans dissemination from the lungs to the CNS. We investigated the impact of METH on C. neoformans dissemination to the brain using a pulmonary model of infection. The fungal counts (Fig. 6A) and quantities of GXM (Fig. 6B) in the brain of METH-treated mice were significantly higher than in control animals 3 days after infection (P Ͻ 0.01). Immunofluorescence staining showed larger lesions and larger amounts of GXM released in the brains of METH-treated mice than in untreated animals (Fig. 6C) . The areas of brain lesions of METH-treated, infected mice reached, on average, 41.87 m 2 Ϯ 3.72 m 2 , whereas lesions of control mice averaged 19.75 m 2 Ϯ 2.55 m 2 (P Ͻ 0.001) (Fig. 6D) .
DISCUSSION
C. neoformans enters the host through the respiratory tract and is nearly universally contained in the setting of intact immunity, whereas the fungus can cause a pulmonary disease that may progress and disseminate to the CNS in immunocompromised hosts, especially in the setting of AIDS. A recent report has revealed a greater risk for tuberculosis (TB) among METH users than nonusers (23) . Similarly, a study of HIV-infected patients in Thailand reported that 40% of those also infected with TB had a history of METH use (24) . In addition, we have demonstrated that METH enhances disease caused by the pathogenic intracellular fungus Histoplasma capsulatum (25) . In the present study, we further investigated whether METH enhances host susceptibility to a pulmonary infection such as cryptococcosis. Our results showed that METH significantly enhances the mortality of C. neoformansinfected mice, fungal burden, and the amount of C. neoformans capsular polysaccharide released in vivo. These findings lead us to hypothesize that METH stimulates fungal biofilm formation in the lungs of treated animals, which may serve as a reservoir for C.
neoformans evasion of immunity, enhancing fungal survival and facilitating subsequent dissemination to the CNS. Recently, Volkow et al. demonstrated that the lungs have the highest METH uptake and most rapid clearance compared to other organs after intravenous injection (8) . METH is associated with elevated free radical formation and significant lung injury (26) . Although we observed a reduction in alveolar space in the lungs of METH-treated mice prior to infection, we recently showed that METH administration does not alter the numbers of neutrophils or macrophages in lung tissues (7) , which may reflect a combination of the sporadic presence of the drug and the responsive migration of these cells in this tissue. Additionally, we have previously shown that METH alters innate immune cell effector functions such as phagocytosis and antigen processing (27, 28) . Our results show that accumulation of METH in the lungs may also contribute by rendering pulmonary tissue more vulner- able to infections due to defects in macrophages and neutrophils. In this regard, our histological analysis of the lungs showed that, in contrast to controls, METH-treated mice displayed low numbers of inflammatory cells in the pulmonary tissue early during infection and large numbers of cryptococci surrounded by vast amounts of polysaccharide in a biofilm-like arrangement 7 days postinfection. Notably, we documented that METH-treated animals had more-accelerated breathing than controls, suggesting respiratory distress due to the infection.
To determine the mechanism by which METH stimulates C. neoformans adhesion to pulmonary tissue, we incubated A549 cells with the drug and evaluated fungal adhesion. We observed that METH enhanced yeast adhesion to these epithelial cells, suggesting that the drug causes cellular alterations in A549 cells. A decrease in the negative surface charge has been shown to increase significantly the adhesion of several microbes to host tissues (29) . This fact may play an important role in the lungs of METHtreated mice, where the increased adherence of C. neoformans in human airways might stimulate biofilm formation, leading to chronic lung infection. In patients with cystic fibrosis, adhesion of bacterial pathogens increases due to a reduction in the negativity of the epithelial cell surface charge (30) . METH might modify the negative charge by membrane phospholipids, surface carbohydrates, and ionized groups of membrane proteins. Although this is beyond the scope of this report, it might be a logical and interesting extension of this work to evaluate in our future investigations.
METH stimulates C. neoformans biofilm formation in vivo. The polysaccharide capsule of C. neoformans is responsible for the high negative charge of the cells (21) . Our zeta potential analysis demonstrates that METH imparts a high negative charge to the cryptococcal surface, which may translate into enhanced interaction with pulmonary tissue colonization or adhesion and yeast cell-cell interactions during biofilm formation (31) . For instance, a mutant of the thermophile Anoxybacillus flavithermus showing a reduced negative charge and hydrophobic cell membrane displayed an impaired ability to adhere to a solid surface (32) . Similarly, we have previously shown that cationic chitosan reduces biofilm formation in C. neoformans (31) and Candida albicans (33) .
The release of the cryptococcal polysaccharide capsule is important for adhesion of the yeast and biofilm development in C. neoformans (13) . An spot ELISA provided an alternate method to confirm the results obtained in vivo and in vitro in establishing the mechanism by which METH promotes C. neoformans colonization and biofilm formation. The numbers and areas of spots on microtiter plates were determined as a function of time using light microscopy. Biofilm formation by C. neoformans did correlate with the number of yeast cells bound to the plastic support surface and GXM released. For instance, C. neoformans biofilms grown in the presence of METH attached in larger quantities to the plastic surface of the microtiter plate and produced larger spots than control biofilms. This result implies that METH stimulates fungal local release of capsular polysaccharide by attached cells and biofilm formation in the respiratory tract. In fact, the combination of extensive C. neoformans capsular polysaccharide release impairs innate immune cell migration (11) , and the immunosuppressive effect of the drug may have detrimental effects on METH users with AIDS.
We assessed the effect of METH on C. neoformans capsular polysaccharide, which is essential for pathogenesis (34) . Interestingly, fungal cells treated with 25 M METH showed a punctate or limited GXM-binding pattern with MAb 18B7, as opposed to the annular pattern exhibited by untreated cells. Studies by Feldmesser et al. (35) showed that differences in levels of GXM binding by MAbs are related to the efficacies of those antibodies in protecting C. neoformans-infected animals. For instance, an annular GXM binding pattern is indicative of protection, whereas punctate binding is indicative of the opposite. Similarly, there were differences in the fluorescence intensities displayed. Untreated cells showed a larger and very well delineated capsule compared to METH-treated cells. In this regard, structural studies using light scattering revealed that capsular polysaccharide molecules on METH-treated fungal cells were shorter than those on their untreated counterparts. Moreover, we observed morehomogeneous fibers of polysaccharide in fungal cells exposed to METH than in control cells. This observation was further supported by a capture ELISA that demonstrated that METH-treated cells released the capsular polysaccharide in significantly higher quantities than untreated cells. Furthermore, we performed structural studies on the exopolysaccharides of untreated and METHtreated C. neoformans cells. Sugar composition analysis of METHtreated yeast cells was remarkable for the predominance of xylose and glucose, whereas untreated capsular polysaccharide consisted of high levels of glucuronic acid, mannose, and galactose. Our results suggest that a drug of abuse may cause alterations in the production of a virulence factor by a pathogen and the adaptive capacity of microorganisms to external stimuli, which can be advantageous to the microbe during pathogenesis.
We investigated the impact of METH on C. neoformans dissemination from the lungs to the CNS using an intratracheal model of METH abuse and infection. C. neoformans is a neurotropic fungus; therefore, our findings demonstrated high numbers of CFU, levels of GXM, and brain lesions in METH-treated mice. METH is present in the brain within 9 min after exposure, and the drug is maintained for protracted periods thereafter (36) . Recently, we showed that METH modifies tight junction and adhesion molecules, increasing the permeability of the BBB and facilitating CNS invasion by C. neoformans using an intravenous model of infection (20) . It is also well documented that METHinduced oxidative stress and hyperthermia are primary factors underlying the damage of neural cells (37, 38) and associated leakage of the BBB. In fact, METH contributes to host neurotoxicity by causing morphological abnormalities to the components of the BBB, therefore, facilitating microbial CNS invasion (37) . Similarly, from the side of the pathogen, we have previously hypothesized that GXM release may also be influenced by Ca 2ϩ sequestration from endothelial cells on the BBB, leading to GXM-mediated BBB disruption and enhanced fungal invasion (20) . Molecular and cellular abnormalities of the cells that compose the BBB (39) may also arise from the interaction and accumulation of fungal cells. In this regard, we have documented increased fungemia in the bloodstream of METH-infected mice. Likewise, C. neoformans can use a "Trojan horse" mechanism (19) to cross the brain vasculature by transmigrating within macrophages, which is also consistent with our model.
In conclusion, METH promotes C. neoformans colonization of the lungs upon infection and subsequent biofilm formation. Our findings suggest that C. neoformans biofilms may act as a fungal reservoir, shielding single cells from phagocytic cells, which can later disseminate, especially to the CNS. Moreover, the drug causes profound defects in the integrity of the BBB in vivo, increasing permeability and facilitating the transmigration of C. neoformans to the CNS. METH-induced alterations to the molecules responsible for maintaining the integrity of the BBB provide an explanation for the susceptibility of a METH abuser to brain infection by HIV and other pathogens. Broadly, METH has diverse and pronounced detrimental effects on host immunity that can also enhance pathogen persistence and proliferation.
MATERIALS AND METHODS
C. neoformans. C. neoformans strain H99 (serotype A) was inoculated in Sabouraud dextrose broth (Difco, MI) and incubated at 30°C for 24 h in a rotary shaker set at 150 rpm (Cole-Parmer, IL). Methamphetamine administration. High-dose-METH users initially take small amounts of the drug intermittently before progressively increasing the dose (40) . To simulate this pattern, increasing doses (2.5, 5, and 10 mg/kg of body weight/day at weeks 1, 2, and 3, respectively) of METH (Sigma, MO) were intraperitoneally (i.p.) administered daily to female C57BL/6 mice (age, 6 to 8 weeks; NCI) over 21 days. Phosphatebuffered saline (PBS)-treated animals were used as controls. Animal care for this study was approved by the Animal Welfare and Research Ethics Committee at the Albert Einstein College of Medicine (protocol number 20110402).
In vivo pulmonary model and C. neoformans infection. At day 21, METH-and PBS-treated C57BL/6 mice were anesthetized with 100 mg/kg ketamine (Ketaset; Fort Dodge, IA) and 10 mg/kg xylazine (AnaSed; Shenandoah, IA). Thereafter, a 100-l suspension containing either 10 6 or 10 7 C. neoformans H99 cells in PBS was inoculated intratracheally (i.t.). For infection with 10 6 cryptococci, animals were euthanized at days 3 and 7 and lung tissues were excised for processing for histology, determination of CFU numbers, and quantification of GXM.
CFU determinations. At day 3 and 7 postchallenge with 10 6 fungal cells, lung tissues were excised from euthanized mice and one lobe of lung was homogenized in sterile PBS. Suspensions were plated on Sabouraud dextrose agar (Difco) and incubated at 30°C for 48 h. Quantification of viable yeast cells was determined by CFU counting.
Histological examinations. At day 3 and 7 postinfection, lung tissues were excised from euthanized mice; the tissues were fixed in 10% formalin for 24 h, processed, and embedded in paraffin. Four-micrometer vertical sections were cut and then fixed to glass slides and subjected either to hematoxylin and eosin (H&E) stain or to mucin carmine (MC) stain, in order to examine tissue and fungal morphology, respectively. Microscopic examinations of tissues were performed by light microscopy.
Human epithelial cells The human type II alveolar-epithelial-cell-like cell line A549 (ATCC, VA) was used in this study. These cells are derived from lung carcinomatous tissue and are widely used in cell models to study infection by respiratory pathogens (41) . The cell cultures were maintained as previously described (27) . A549 cells were then incubated in the absence or the presence of 25 M METH for 2 h at 37°C in 5% CO 2 . C. neoformans adhesion was assessed by CFU determination as previously described (27) .
C. neoformans capsular polysaccharide determinations. C. neoformans capsular GXM released in pulmonary tissue and culture was measured by capture ELISA as described previously (22) .
Capsule measurement. An aliquot of 10 l of untreated or METHtreated yeast cells was mixed with India ink and visualized with light microscopy. The capsule size of 100 cells was measured in these images using ImageJ 1.39u software (NIH). Capsule size was defined as the difference between the diameter of the total cell (capsule included) and the cell body diameter, defined by the cell wall.
